Sangamo Therapeutics Share Price (NASDAQ: SGMO)

$0.52

▲

-0.02

(-3.7%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Sangamo Therapeutics Stock chart to analyse performance

Sangamo Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$0.52
Today's High:$0.53
$0.52
0.79%
Downside
Day's Volatility :3.21%
Upside
2.44%
52 Weeks Low:$0.41
52 Weeks High:$3.18
$0.52
20.94%
Downside
52 Weeks Volatility :87.07%
Upside
83.64%

Sangamo Therapeutics Stock Returns

Period	Sangamo Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	10.02%	3.6%	0.0%
6 Months	-43.48%	-7.7%	0.0%
1 Year	-35.7%	-12.6%	0.0%
3 Years	-90.66%	10.2%	-4.1%

Sangamo Therapeutics, Inc. Key Stats

Check Sangamo Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.54
Open	$0.533
Today's High	$0.533
Today's Low	$0.5159
Market Capitalization	$156.9M
Today's Volume	$3.5M
52 Week High	$3.179
52 Week Low	$0.4111
Revenue TTM	$81.7M
EBITDA	$-58.3M
Earnings Per Share (EPS)	$-0.26
Profit Margin	-77.48%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-292.47%

Stock Returns calculator for Sangamo Therapeutics Stock including INR - Dollar returns

The Sangamo Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Sangamo Therapeutics investment value today

Current value as on today

₹69,482

Returns

₹30,518

(-30.52%)

Returns from Sangamo Therapeutics Stock

₹35,802 (-35.8%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Sangamo Therapeutics Stock

-19%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Sangamo Therapeutics Stock from India on INDmoney has decreased by -19% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Sangamo Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
3.44%
Wasatch Advisors LP
2.96%
BlackRock Inc
2.00%
Renaissance Technologies Corp
1.16%
Geode Capital Management, LLC
0.84%
Ikarian Capital, LLC
0.68%

Analyst Recommendation on Sangamo Therapeutics Stock

Rating

Trend

Buy

66%Buy

33%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Sangamo Therapeutics(by analysts ranked 0 to 5 stars)

Sangamo Therapeutics Share Price Target

What analysts predicted

Upside of 688.46%

Target:

$4.10

Current:

$0.52

Sangamo Therapeutics share price target is $4.10, a slight Upside of 688.46% compared to current price of $0.52 as per analysts' prediction.

Sangamo Therapeutics Stock Insights

Price Movement
In the last 7 days, SGMO stock has moved down by -11.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 6.43M → 18.30M (in $), with an average increase of 64.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -30.59M → -19.98M (in $), with an average increase of 53.1% per quarter
SGMO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 108.5%
SGMO vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 206.4%
Price to Sales
ForSGMO every $1 of sales, investors are willing to pay $1.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Sangamo Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$102.4M	↑ 21.29%
Net Income	$-75.8M	↑ 10.95%
Net Profit Margin	-74.02%	↑ 6.89%

	FY20	Y/Y Change
Revenue	$118.2M	↑ 15.39%
Net Income	$-121.1M	↑ 59.75%
Net Profit Margin	-102.48%	↓ 28.46%

	FY21	Y/Y Change
Revenue	$110.7M	↓ 6.34%
Net Income	$-178.3M	↑ 47.2%
Net Profit Margin	-161.06%	↓ 58.58%

	FY22	Y/Y Change
Revenue	$111.3M	↑ 0.54%
Net Income	$-192.3M	↑ 7.84%
Net Profit Margin	-172.76%	↓ 11.7%

	FY23	Y/Y Change
Revenue	$176.2M	↑ 58.34%
Net Income	$-257.8M	↑ 34.09%
Net Profit Margin	-146.3%	↑ 26.46%

	FY24	Y/Y Change
Revenue	$57.8M	↓ 67.2%
Net Income	$-97.9M	↓ 62.01%
Net Profit Margin	-169.45%	↓ 23.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$481.0K	↓ 76.44%
Net Income	$-49.1M	↓ 18.59%
Net Profit Margin	-10.2K%	↓ 7252.87%

	Q2 FY24	Q/Q Change
Revenue	$356.0K	↓ 25.99%
Net Income	$-36.1M	↓ 26.4%
Net Profit Margin	-10.1K%	↑ 57.3%

	Q3 FY24	Q/Q Change
Revenue	$49.4M	↑ 13779.78%
Net Income	$10.7M	↓ 129.54%
Net Profit Margin	21.6%	↑ 10169.91%

	Q4 FY24	Q/Q Change
Revenue	$7.6M	↓ 84.72%
Net Income	$-23.4M	↓ 319.23%
Net Profit Margin	-309.84%	↓ 331.44%

	Q1 FY25	Q/Q Change
Revenue	$6.4M	↓ 14.75%
Net Income	$-30.6M	↑ 30.78%
Net Profit Margin	-475.33%	↓ 165.49%

	Q2 FY25	Q/Q Change
Revenue	$18.3M	↑ 184.39%
Net Income	$-20.0M	↓ 34.68%
Net Profit Margin	-109.18%	↑ 366.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$102.4M	↑ 21.29%

	FY20	Y/Y Change
Profit	$118.2M	↑ 15.39%

	FY21	Y/Y Change
Profit	$110.7M	↓ 6.34%

	FY22	Y/Y Change
Profit	$111.3M	↑ 0.54%

	FY23	Y/Y Change
Profit	$154.0M	↑ 38.4%

	FY24	Y/Y Change
Profit	$57.8M	↓ 62.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-2.0M	↑ 117.55%

	Q2 FY24	Q/Q Change
Profit	$-23.9M	↑ 1067.09%

	Q3 FY24	Q/Q Change
Profit	$47.3M	↓ 298.12%

	Q4 FY24	Q/Q Change
Profit	$7.6M	↓ 84.03%

	Q1 FY25	Q/Q Change
Profit	$6.4M	↓ 14.75%

	Q2 FY25	Q/Q Change
Profit	$18.3M	↑ 184.39%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-144.4M	↓ 488.68%
Investing Cash Flow	$-59.8M	↓ 66.42%
Financing Cash Flow	$142.0M	↓ 38.7%

	FY20	Y/Y Change
Operating Cash Flow	$169.9M	↓ 217.64%
Investing Cash Flow	$-271.6M	↑ 354.22%
Financing Cash Flow	$153.1M	↑ 7.79%

	FY21	Y/Y Change
Operating Cash Flow	$-233.3M	↓ 237.31%
Investing Cash Flow	$248.2M	↓ 191.37%
Financing Cash Flow	$32.9M	↓ 78.54%

	FY22	Y/Y Change
Operating Cash Flow	$-223.6M	↓ 4.13%
Investing Cash Flow	$59.3M	↓ 76.11%
Financing Cash Flow	$84.7M	↑ 157.65%

	FY23	Y/Y Change
Operating Cash Flow	$-224.8M	↑ 0.54%
Investing Cash Flow	$153.5M	↑ 158.97%
Financing Cash Flow	$14.6M	↓ 82.77%

	FY24	Y/Y Change
Operating Cash Flow	$-67.1M	↓ 70.14%
Investing Cash Flow	$37.5M	↓ 75.56%
Financing Cash Flow	$28.4M	↑ 94.52%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-48.7M	↓ 3.71%
Investing Cash Flow	$35.8M	↓ 4.95%
Financing Cash Flow	$22.1M	↑ 13146.71%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-26.9M	↓ 44.75%
Investing Cash Flow	$127.0K	↓ 99.65%
Financing Cash Flow	$-533.0K	↓ 102.41%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$11.8M	↓ 143.74%
Investing Cash Flow	$233.0K	↑ 83.46%
Financing Cash Flow	$-203.0K	↓ 61.91%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-3.4M	↓ 128.5%
Investing Cash Flow	$1.3M	↑ 468.24%
Financing Cash Flow	$7.0M	↓ 3543.84%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-18.2M	↓ 30.56%
Investing Cash Flow	$-24.0K	-
Financing Cash Flow	$28.6M	↑ 251.78%

Sangamo Therapeutics Technicals Summary

Sell

Neutral

Buy

Sangamo Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Sangamo Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Sangamo Therapeutics, Inc.	-7.35%	-43.48%	-35.7%	-90.66%	-95.14%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Sangamo Therapeutics, Inc.	NA	NA	0.0	-0.41	-2.92	-0.41	NA	0.07
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Sangamo Therapeutics, Inc.	Buy	$156.9M	-95.14%	NA	-77.48%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Organization	Sangamo Therapeutics
Employees	183
CEO	Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Industry	Health Technology

Key Management of Sangamo Therapeutics, Inc.

Name	Title
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.	CEO, President & Director
Ms. Prathyusha Duraibabu CPA, M.B.A.	Senior VP, CFO & Principal Accounting Officer
Mr. Scott B. Willoughby	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Nathalie Dubois-Stringfellow Ph.D.	Senior VP & Chief Development Officer
Mr. Gregory Davis Ph.D.	Head of Research & Technology
Ms. Louise Wilkie	Head of Global Corporate Communications & Investor Relations
Mr. Phillip Ramsey	Chief Technical Officer
Ms. Stephanie J. Seiler CLP	VP and Head of Business Development & Alliance Management
Mr. David Ojala	Scientist II - Discovery & Translational Research

Important FAQs about investing in SGMO Stock from India :

What is Sangamo Therapeutics share price today?

Sangamo Therapeutics share price today is $0.52 as on August 30, 2025 at 1:29 am IST at the close of the market. Sangamo Therapeutics share today touched a day high of $0.53 and a low of $0.52.

What is the 52 week high and 52 week low for Sangamo Therapeutics share?

Sangamo Therapeutics share touched a 52 week high of $3.18 and a 52 week low of $0.41. Sangamo Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $0.52, lower by 83.64% versus the 52 week high.

How to invest in Sangamo Therapeutics Stock (SGMO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sangamo Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sangamo Therapeutics Shares that will get you 2.8846 shares as per Sangamo Therapeutics share price of $0.52 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Sangamo Therapeutics Stock (SGMO) from India?

Indian investors can start investing in Sangamo Therapeutics (SGMO) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Sangamo Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Sangamo Therapeutics share’s latest price of $0.52 as on August 30, 2025 at 1:29 am IST, you will get 19.2308 shares of Sangamo Therapeutics. Learn more about fractional shares .

What are the returns that Sangamo Therapeutics has given to Indian investors in the last 5 years?

Sangamo Therapeutics stock has given -95.14% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?